パーブル・バイオテックのニュース一覧

Purple Biotech Identifies Potential New Serum Biomarker For Its Lead Oncology Therapeutic Candidate CM24: Associated With 79% Reduction In Risk Of Death

Benzinga11/04 21:00

12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga11/02 04:36

Purple Biotech Shares Are Trading Lower. The Company Presented New Data Regarding Its Tri-specific Antibody Platform CAPTN-3.

Benzinga10/26 03:46

HC Wainwright & Co. Maintains Buy on Purple Biotech, Adjusts Price Target To $33 (1-20 Reverse Stock Split)

Benzinga09/21 01:38

H.C. Wainwrightはパーブル・バイオテック(PPBT.US)のレーティングを強気に据え置き、目標株価を33ドルに引き下げた

H.C. WainwrightのアナリストEmily Bodnarは$Purple Biotech(PPBT.US)$のレーティングを強気に据え置き、目標株価を200ドルから33ドルに引き下げた。TipRanksのデータによると、このアナリストの最近1年間の的中率は36.3%、平均リターンは19.6%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターン

Futuニュース09/19 18:31

Purple Biotech Says Pancreatic Cancer Study Data Shows CM24 With Nivolumab and Chemo Improves Survival

MT Newswires09/18 19:42

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket

Benzinga09/16 18:07

Purple Biotech Plans To Change Ratio Of ADS To Ordinary Shares To ADS Ratio Of 1 ADS Representing 200 Ordinary Shares

Benzinga09/12 04:19

Purple Biotech Is Maintained at Buy by HC Wainwright & Co.

Dow Jones08/19 19:53

Purple Biotech 2Q Net $2.42M >PPBT

Dow Jones08/16 20:12

Purple Biotech 2Q EPS 9c >PPBT

Dow Jones08/16 20:12

Purple Biotech Gets Extension to Regain Nasdaq Compliance

MT Newswires07/26 02:44

Purple Biotech Receives Extension From Listing Qualifications Department Of Nasdaq To Regain Compliance With Minimum $1.00 Bid Price Requirement

Benzinga07/25 19:39

Purple Biotech Receives Extension to Regain Compliance With the Nasdaq's Minimum Bid Price Rule

Globe Newswire07/25 19:35

Purple Biotech Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones07/12 01:34

Why Purple Biotech (PPBT) Shares Are Trading Lower

Benzinga07/02 02:21

Purple Biotech Shares Are Trading Lower After the Company Announced the Exercise of Warrants for $2 Million Gross Proceeds.

Benzinga07/02 00:41

Purple Biotech Exercises Warrants For $2M Gross Proceeds

Benzinga07/01 21:09

Purple Biotech Announces Positive Data From Phase 2 Study Of CM24 In Combination With Nivolumab

RTTNews06/27 21:32

Purple Biotech Reports Interim Results From Randomized Phase 2 Pancreatic Cancer Study; Says Concordant And Consistent Improvement In Primary And All Secondary Endpoints Are Compelling

Benzinga06/27 19:54